Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Stocktreeon May 14, 2021 9:54am
141 Views
Post# 33202677

Company and Stockhouse plants BS continues!!!!!!

Company and Stockhouse plants BS continues!!!!!!
Some apparently very happy folks this morning.

The truth: the company is lying. They say they still expect to complete the Tigris trial in 2022.
They currently have 15 patients randomized over 150.
They  announced the trial was approved in Feb. 2019. That is over 2 years for a tenth of the population required.

So multiply that 2 years by 10 and... while I don't expect this trial to end in 18 years, there is no way it will be completed in 2022.

And as for the company's history with information like "we are very happy with the data":
that's a big fat PASS.

If they had started packing a profit with what they already have in hand and fits perfectly with the health crisis we are in, I would be slightly less pessimistic about them. But I do not believe a second today's news will attract some big players, however you spin it with exclamation marks and, down the road fake innuendos wrapped in pumping BS.
<< Previous
Bullboard Posts
Next >>